BMB Reports Papers in Press available online.

Search Papers In Press
This galley proof is being listed electronically before publishing the final manuscript (It's not final version).

 
JMJD4 promotes tumor progression via inhibition of the PDCD5–TP53 pathway
Hyunsik Kim 1,# (Research worker), Subhin Jang2,# (Research worker), Soo Yeon Lee1 (Research worker), Jae-Hwan Kwon1 (Research worker), Seunghee Byun1 (Research worker), Jung-Yoon Yoo3 (Professor), Sungryul Yu4 (Professor), Soo-Yeon Park 1 (Research worker), Ho-Geun Yoon 1,* (Professor)
1Department of Biochemistry and Molecular Biology, Brain Korea 21 Project, Yonsei University College of Medicine,
2Process Research Team, R&D Division, CHA Biotech,
3Department of Biomedical Laboratory Science, Yonsei University MIRAE Campus,
4Department of Clinical Laboratory Science, Semyung University
Abstract
Programmed cell death 5 (PDCD5) regulates cell death and suppresses tumor progression. Since the stability and nuclear translocation of PDCD5 are regulated by TP53-dependent cell death stimuli, knowledge of the regulatory mechanism of PDCD5 function is required to better understand the TP53-signaling pathway. We identified Jumonji domain–containing protein 4 (JMJD4) to be a PDCD5-interacting protein using liquid chromatography–mass spectrometry (LC-MS). Interestingly, JMJD4 upregulates cell proliferation and chemo-resistance under genotoxic stress conditions by colony-formation assay and decreases TP53-related apoptotic genes (BAX, PUMA) by suppressing protein levels of PDCD5. Additionally, using the Cancer Genome Atlas and the Gene Expression Omnibus database to confirm the clinical correlation between JMJD4 and cancer patients, we verified that JMJD4 is associated with a poor prognosis in colon cancer and lung cancer patients. Therefore, this study demonstrates that JMJD4 directly interacts with PDCD5, regulates cancer cell death negatively, and could be a potential therapeutic target for cancer development.
Abstract, Accepted Manuscript [Submitted on February 15, 2024, Accepted on April 23, 2024]
  © KSBMB. All rights reserved. / Powered by INFOrang Co., Ltd